Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 2436 | 1.330 |
Why?
|
| Pyridines | 8 | 2021 | 309 | 1.230 |
Why?
|
| Breast Neoplasms | 17 | 2024 | 2887 | 1.190 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 621 | 0.880 |
Why?
|
| Receptor, ErbB-2 | 7 | 2024 | 223 | 0.860 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2357 | 0.780 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 317 | 0.710 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 426 | 0.680 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 137 | 0.680 |
Why?
|
| Benzenesulfonates | 2 | 2008 | 66 | 0.610 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 639 | 0.460 |
Why?
|
| Carcinoma, Small Cell | 2 | 2017 | 134 | 0.440 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 2261 | 0.430 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 53 | 0.420 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 1720 | 0.420 |
Why?
|
| Capecitabine | 3 | 2021 | 96 | 0.400 |
Why?
|
| Bevacizumab | 8 | 2022 | 281 | 0.380 |
Why?
|
| Students, Medical | 3 | 2023 | 384 | 0.380 |
Why?
|
| Neoplasms | 6 | 2023 | 2897 | 0.370 |
Why?
|
| Medical Oncology | 3 | 2019 | 359 | 0.360 |
Why?
|
| Radiosurgery | 3 | 2021 | 272 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 864 | 0.350 |
Why?
|
| Receptors, Estrogen | 3 | 2024 | 384 | 0.350 |
Why?
|
| Anilides | 3 | 2019 | 47 | 0.340 |
Why?
|
| Middle Aged | 28 | 2024 | 25017 | 0.340 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 6501 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1074 | 0.330 |
Why?
|
| Aged | 24 | 2024 | 18402 | 0.320 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 167 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2023 | 468 | 0.320 |
Why?
|
| Humans | 46 | 2024 | 86601 | 0.300 |
Why?
|
| Prostatectomy | 2 | 2021 | 471 | 0.300 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 322 | 0.290 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 70 | 0.290 |
Why?
|
| Neoplasm Staging | 9 | 2023 | 1937 | 0.280 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 302 | 0.280 |
Why?
|
| Female | 31 | 2024 | 44507 | 0.270 |
Why?
|
| Pyrroles | 2 | 2017 | 184 | 0.270 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 160 | 0.260 |
Why?
|
| Indoles | 2 | 2017 | 318 | 0.260 |
Why?
|
| Neutropenia | 3 | 2021 | 215 | 0.260 |
Why?
|
| Nitriles | 3 | 2024 | 149 | 0.250 |
Why?
|
| Trastuzumab | 2 | 2021 | 68 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 589 | 0.230 |
Why?
|
| Piperazines | 2 | 2021 | 272 | 0.230 |
Why?
|
| Watchful Waiting | 2 | 2022 | 60 | 0.230 |
Why?
|
| Adult | 19 | 2023 | 25640 | 0.220 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 144 | 0.220 |
Why?
|
| Vegetables | 2 | 2020 | 45 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1313 | 0.210 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 20 | 0.210 |
Why?
|
| Schools, Medical | 2 | 2023 | 123 | 0.210 |
Why?
|
| ErbB Receptors | 1 | 2005 | 485 | 0.210 |
Why?
|
| Oxazoles | 1 | 2021 | 19 | 0.200 |
Why?
|
| Clinical Competence | 2 | 2018 | 751 | 0.200 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 111 | 0.200 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.190 |
Why?
|
| Postmenopause | 2 | 2024 | 98 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 150 | 0.190 |
Why?
|
| Triazoles | 2 | 2024 | 96 | 0.190 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 77 | 0.190 |
Why?
|
| Male | 20 | 2023 | 40956 | 0.190 |
Why?
|
| Quinazolines | 1 | 2021 | 220 | 0.180 |
Why?
|
| Leukemia | 1 | 2022 | 320 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 199 | 0.180 |
Why?
|
| Testosterone | 1 | 2021 | 271 | 0.180 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1056 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 236 | 0.170 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.160 |
Why?
|
| Counseling | 1 | 2020 | 145 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 126 | 0.160 |
Why?
|
| Age Factors | 1 | 2023 | 1849 | 0.160 |
Why?
|
| Diet | 2 | 2022 | 443 | 0.160 |
Why?
|
| Disease-Free Survival | 5 | 2021 | 1204 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 311 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2023 | 4210 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2021 | 1538 | 0.160 |
Why?
|
| Niacinamide | 2 | 2008 | 116 | 0.150 |
Why?
|
| Phenylurea Compounds | 2 | 2008 | 113 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1464 | 0.150 |
Why?
|
| Double-Blind Method | 4 | 2021 | 1823 | 0.150 |
Why?
|
| Curriculum | 2 | 2019 | 539 | 0.150 |
Why?
|
| Carboplatin | 4 | 2022 | 286 | 0.150 |
Why?
|
| Disease Progression | 5 | 2021 | 1531 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2023 | 7988 | 0.150 |
Why?
|
| Paclitaxel | 4 | 2022 | 460 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 100 | 0.150 |
Why?
|
| Survival Rate | 5 | 2019 | 1860 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 2016 | 19 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 202 | 0.140 |
Why?
|
| Prognosis | 5 | 2023 | 3674 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1376 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3352 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2016 | 154 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 369 | 0.120 |
Why?
|
| Pediatrics | 1 | 2018 | 344 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2018 | 334 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 266 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2016 | 373 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1169 | 0.110 |
Why?
|
| Quality of Life | 4 | 2022 | 1583 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 857 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3636 | 0.100 |
Why?
|
| Hospitalization | 1 | 2016 | 848 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 169 | 0.090 |
Why?
|
| Fatigue | 3 | 2017 | 174 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1169 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2018 | 1004 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1685 | 0.080 |
Why?
|
| Placebos | 1 | 2008 | 218 | 0.080 |
Why?
|
| Oncogenes | 1 | 2007 | 88 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 261 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 352 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 740 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2021 | 237 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2007 | 502 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2019 | 839 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 183 | 0.060 |
Why?
|
| Young Adult | 3 | 2021 | 5974 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 64 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 2767 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 916 | 0.060 |
Why?
|
| Risk Factors | 3 | 2020 | 5416 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.060 |
Why?
|
| Abiraterone Acetate | 1 | 2023 | 11 | 0.060 |
Why?
|
| Contrast Media | 1 | 2008 | 1077 | 0.060 |
Why?
|
| Prednisone | 1 | 2023 | 258 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2023 | 92 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5209 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 291 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2501 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 58 | 0.050 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 13 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8475 | 0.050 |
Why?
|
| Breast | 1 | 2023 | 286 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2021 | 81 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 162 | 0.050 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
| Perception | 1 | 2021 | 168 | 0.050 |
Why?
|
| Telephone | 1 | 2020 | 32 | 0.050 |
Why?
|
| Learning | 1 | 2023 | 280 | 0.050 |
Why?
|
| Mastectomy | 1 | 2021 | 236 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 274 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 202 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 353 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 612 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 377 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 168 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hemoptysis | 1 | 2018 | 24 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 21 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 121 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 329 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Celecoxib | 1 | 2017 | 31 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2017 | 69 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 930 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2017 | 76 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 382 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 31 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 270 | 0.040 |
Why?
|
| Mucositis | 1 | 2017 | 17 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 72 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2019 | 225 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 1141 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2007 | 3241 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2017 | 35 | 0.040 |
Why?
|
| United States | 2 | 2020 | 6665 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 297 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 76 | 0.040 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2018 | 678 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 580 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 128 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 78 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1850 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 130 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1718 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 299 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1576 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 295 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1161 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2261 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 722 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2356 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2016 | 534 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1961 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 556 | 0.020 |
Why?
|
| Child | 1 | 2018 | 6926 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1379 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 3967 | 0.010 |
Why?
|